Atlas FDA

Optilume™ BPH Catheter System

FDA premarket approval P220029 · decided 2023-06-30

Approval details

PMA number
P220029
Trade name
Optilume™ BPH Catheter System
Generic name
Drug coated prostatic dilation catheter for benign prostatic hyperplasia
Applicant
Urotronic, Inc.
Date received
2022-12-12
Decision date
2023-06-30
Days to decision
200 days
Decision code
APPR
Product code
QXB
Advisory committee
Gastroenterology, Urology
Expedited review
No
Location
Minneapolis, MN
Statement
Approval for the Optilume BPH Catheter System indicated for the treatment of obstructive urinary symptoms associated with Benign Prostatic Hyperplasia (BPH) in men >= 50 years of age.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Optilume® High Pressure Urological Balloon Dilation Catheter (K250910)Urotronic, Inc.2025-05-22
Optilume Basic Urological Balloon Dilation Catheter (K191061)Urotronic, Inc.2020-01-02